BBL
UTHR icon

Beck Bode LLC’s United Therapeutics UTHR Stock Holding History

Beck Bode LLC’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,084
Closed -$2.58M – 133
2024
Q2 		$2.58M Buy
8,084
+79
+1% +$20.9K 0.52% 43
2024
Q1 		$1.84M Buy
+8,005
New +$1.81M 0.38% 67
2021
Q4 		– Sell
-28,286
Closed -$5.22M – 103
2021
Q3 		$5.22M Buy
+28,286
New +$5.57M 1.46% 29

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Beck Bode LLC's UTHR Position: Q3 2024 in Review

Beck Bode LLC sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 8,084 shares — an estimated $2.58M sold.

Beck Bode LLC first reported a position in UTHR in Q3 2021 and held it in 3 quarters. The position peaked at $5.22M in Q3 2021. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • Beck Bode LLC reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Beck Bode LLC sold 8,084 United Therapeutics shares in Q3 2024, an estimated $2.58M.
  • Beck Bode LLC first reported a position in United Therapeutics in Q3 2021 and held it in 3 quarters.
  • Beck Bode LLC's United Therapeutics position peaked at $5.22M in Q3 2021.
  • 625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Beck Bode LLC's 13F filing for Q3 2024, filed 12 Nov 2024.